Bio€quity Europe 2012

Published: 16-May-2012

15 - 16 May 2012
Conference
Frankfurt, Germany

BioEquity 2012 is the leading venue for public and private biotech investors throughout Europe. Together, BioCentury Publications, EBD Group, and BIO will be producing the 13th edition of this annual international conference

Organiser: EBD Group

Trending Articles

  1. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Interphex 16-18 April 2024 | Conference and Exhibition | New York, US
  4. Vision Pharma <b>28 February - 1 March 2012</b><br> <i>Exhibition</i><br> Messe Karlsruhe, Germany
  5. Advanced Characterisation Techniques for Solid Pharmaceutical Dosage Forms <b>5 July 2013</b><br> <i>PSSRC Open Day</i><br> University of Lille, France

You may also like

Regulatory

Takeda announces its intention to acquire TiGenix

Takeda Pharmaceutical has announced its intention to launch a voluntary conditional takeover bid on TiGenix, an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions
Manufacturing

TiGenix expands manufacturing facility

TiGenix obtains commercial production licence for expanded manufacturing facility, to provide the capacity for potential European commercial roll out of investigational stem cell therapy, Cx601; the expansion also secures manufacturing for other pipeline products
Research & Development

TiGenix partners with US and EU patient advocacy groups focused on Crohn's disease and ulcerative colitis

Joins the Crohn's and Colitis Foundation's President's Corporate Circle
Research & Development

Takeda makes €10 million equity investment in TiGenix

Takeda Pharmaceuticals International AG will be subscribing 11,651,778 new ordinary shares at an issue price of €0.858 (rounded) per new share
Finance

TiGenix to acquire Coretherapix for €6.7m

Expands its pipeline and enters the cardiology field with purchase of cell therapy company
Manufacturing

Lonza to manufacture Crohn's Disease treatment for TiGenix clinical trial in US

Cx601 product is currently in Phase III trials in Europe
Manufacturing

TiGenix to sell Dutch manufacturing facility to PharmaCell

Facility will continue to manufacture cell therapy cartilage regeneration treatment ChondroCelect for TiGenix
Subscribe now